CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
CytRx Corporation (OTCQB: CYTR) has announced a dividend of one one-thousandth of a share of its newly designated Series D Preferred Stock for each outstanding share of common stock as of May 20, 2022. The Series D Preferred Stock, which carries substantial voting power concerning a proposed reverse stock split, will be non-transferable except alongside common stock transfers. Unused shares will be automatically redeemed if not present at the stockholder meeting. Additional details will be provided in a forthcoming 8-K report to the SEC.
- Dividend declared of Series D Preferred Stock may enhance shareholder engagement.
- Voting power of Series D Preferred Stock allows shareholders to influence key corporate decisions, such as reverse stock split.
- Potential dilution of common stock value if reverse stock split is approved.
- Automatic redemption of Series D Preferred Stock raises concerns about shareholder participation.
All shares of Series D Preferred Stock that are not present in person or by proxy at the meeting of stockholders held to vote on the reverse stock split as of immediately prior to the opening of the polls at such meeting will automatically be redeemed by the Company. Any outstanding shares of Series D Preferred Stock that have not been so redeemed will be redeemed if such redemption is ordered by the Company’s Board of Directors or automatically upon the approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation effecting the reverse stock split at such meeting.
The Series D Preferred Stock will be uncertificated, and no shares of Series D Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Company’s common stock held by such holder. In that case, a number of one one-thousandths of a share of Series D Preferred Stock equal to the number of shares of the Company’s common stock to be transferred by such holder would be transferred to the transferee of such shares of common stock.
Further details regarding the Series D Preferred Stock will be contained in a report on Form 8-K to be filed by the Company with the
Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only CytRx’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of CytRx’s control. Forward-looking statements often include words such as “anticipates,” “estimates,” “expects,” “projects,” “forecasts”, “intends,” “plans,” “believes”, “suggest”, “estimate”, “target”, “should”, “could”, “would”, “may”, “might”, or “will” and words and terms of similar import. Forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside our control. Forward-looking statements include, but are not limited to, statements about our market opportunity and the potential growth of that market, potential receipt of EMA and FDA approvals, potential receipt of future milestone and royalty payments, our strategies (including with regard to stock splits), and trends in our industry and markets, all of which may be affected by, among others, adverse changes in general economic and market conditions. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements; and other risks and uncertainties described in the most recent annual and quarterly reports filed by the
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005996/en/
cytrx@longacresquare.com
Source:
FAQ
What is the current status of CytRx Corporation's Series D Preferred Stock?
What voting rights does the Series D Preferred Stock have for CytRx shareholders?
When will the shareholders vote on the reverse stock split for CytRx?
What happens to the Series D Preferred Stock that is not voted?